Clinical Trial Update: Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lifileucel with reduced-dose fludarabine/cyclophosphamide lymphodepletion and interleukin-2 for unresectable or metastatic melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Melanoma
• Unresectable Melanoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Fludarabine (Fludarabine)
• Interleukin-2 (interleukin-2)
• Lifileucel (autologous tumor-infiltrating lymphocytes (TIL) therapy)

Snippet

Sponsor: University of Kansas Medical Center | Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma | Phase 2 | Status: UNKNOWN